ArticleWorld journal of oncology2019
Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
Article in World journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Pooled it
- Prognostic significance of the Gustave Roussy immune (GRIm) score in cancer patients: a meta-analysis.Annals of medicine · 2023Pooled it
- Pooled it
- Pooled it
- Construction and validation of a nomogram for hepatocellular carcinoma patients based on HCC-GRIm score.Journal of cancer research and clinical oncology · 2023Trial
- Prognostic Value of the Royal Marsden Hospital Score in Patients with De Novo Metastatic Colorectal Cancer Receiving First-Line Systemic Therapy.Journal of clinical medicine · 2026Article
- Prognostic Value of the Gustave Roussy Immune Score in Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line, Immune-Based Combinations.Cancer reports (Hoboken, N.J.) · 2026Article
- Real-world survival outcomes with first-line chemoimmunotherapy and biomarker analysis in extensive-stage small-cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Integration of the GRIm Score with Pathologic Immune and Stromal Markers to Develop a Combined Prognostic Model in Gastric Cancer: A Retrospective Single-Center Study.Medicina (Kaunas, Lithuania) · 2026Article
- Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma.Journal of cancer research and clinical oncology · 2026Article
- Survival of patients with advanced hepatocellular carcinoma based on Gustave Roussy immune score and portal vein tumor thrombosis: a single-center, retrospective, non-randomized case-controlled study.Discover oncology · 2025Article
- The modified-Gustave Roussy immune score: assessing immune prognosis in advanced gastric cancer patients at baseline.Future oncology (London, England) · 2025Article
- A Real-World Evaluation of Clinical Prognostic Scores in Advanced Melanoma Treated with Immune Checkpoint Inhibitors.Journal of clinical medicine · 2025Article
- Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset.Clinical & experimental metastasis · 2025Article
- Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study.Annals of surgical oncology · 2024Article
- The Gustave Roussy Immune score is a powerful biomarker for predicting therapeutic resistance to chemotherapy in gastric cancer patients.Cancer chemotherapy and pharmacology · 2024Article
- How General and Inflammatory Status Impacts on the Prognosis of Patients Affected by Lung Cancer: State of the Art.Biomedicines · 2024Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Gustave Roussy Immune Score (GRIm-Score) and the Royal Marsden Hospital prognostic score (RMH score) were recently developed in order to improve a better participant selection for phase I trials. The GRIm-Score is formed by combination of lactate dehydrogenase (LDH), serum albumin concentration, and neutrophil-to-lymphocyte ratio (NLR). The RMH score is calculated by LDH, albumin, and number of metastases. These two scores have been validated only in phase I trials. The purpose of this study was to assess whether these scores are useful for practical treatment of immune-checkpoint inhibitor (ICI) monotherapy in pretreated non-small cell lung cancer (NSCLC).
methodsThis was a retrospective and single-centered study of 76 NSCLC patients treated with ICI monotherapy between December 2015 and October 2018 at our hospital. We divided 76 patients into high and low GRIm-Score and RMH score groups. Comparison of overall survival (OS) and progression free survival (PFS) was performed by Kaplan-Meier curves and log-rank tests. Independent prognostic factors of OS and PFS were analyzed by multivariate Cox proportional hazard analyses.
resultsThe OS of the high GRIm-Score group was significantly shorter than that of the low score group (low vs. high; median 19.9 vs. 3.2 months, P < 0.01), while no significant difference was observed in PFS (2.6 vs. 2.1 months, P = 0.13). The PFS of the high RMH score was significantly shorter than that of the low score group (low vs. high; 2.6 vs. 1.8 months, P = 0.01), while there was no significant difference in OS (16.0 vs. 10.4, P = 0.24). Multivariate analyses detected high GRIm-Score (hazard ratio (HR) 3.93, 95% confidence interval (CI) 2.04 - 7.58, P < 0.01), and high RMH score (HR 1.76, 95% CI 1.03 - 3.02, P = 0.04) as poor prognostic factors of OS and PFS, respectively.
conclusionsBaseline GRIm-Score and RMH score were independent prognostic factors of OS and PFS of ICI monotherapy for pretreated NSCLC patients, respectively. These two scores are not only selection biomarkers for patients in experimental trials, but also useful prognostic biomarkers for NSCLC patients practically treated with ICI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.